Evidence map›Paper›PMID 41596701›Full record

ReviewInternational journal of molecular sciences2026

Platelet-Rich Plasma from the Research to the Clinical Arena: A Journey Toward the Precision Regenerative Medicine.

Elisabetta Mormone, Vittoria D'Esposito, Paola De Luca, Fulvio E O Ferrara, Francesca P Bellotti, Pietro Formisano, Eugenio Caradonna

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Elisabetta MormoneInstitute for Stem Cell Biology, Regenerative Medicine and Innovative Therapies (ISBReMIT), Fondazione IRCCS "Casa Sollievo della Sofferenza", 71013 San Giovanni Rotondo, Italy.ORCID 0000-0001-5901-3760
Vittoria D'EspositoInstitute of Endotypes in Oncology, Metabolism and Immunology "G. Salvatore"-National Research Council (IEOMI-CNR), Via Pansini 5, 80131 Naples, Italy.ORCID 0000-0002-3675-8062
Paola De LucaOrthopaedic Biotechnology Lab, IRCCS Ospedale Galeazzi-Sant'Ambrogio, Via Cristina Belgioioso 173, 20157 Milan, Italy.ORCID 0000-0001-9810-8818
Fulvio E O FerraraLaboratory Medicine Department, CDI-Centro Diagnostico Italiano, Via Saint Bon 20, 20147 Milan, Italy.ORCID 0000-0002-5425-4335
Francesca P BellottiInstitute for Stem Cell Biology, Regenerative Medicine and Innovative Therapies (ISBReMIT), Fondazione IRCCS "Casa Sollievo della Sofferenza", 71013 San Giovanni Rotondo, Italy.
Pietro FormisanoDepartment of Translational Medicine, University of Naples "Federico II", Via Pansini 5, 80131 Naples, Italy.
Eugenio CaradonnaLaboratory Medicine Department, CDI-Centro Diagnostico Italiano, Via Saint Bon 20, 20147 Milan, Italy.ORCID 0000-0001-9729-6722

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Platelet-rich plasma (PRP) is a cornerstone of regenerative medicine, offering therapeutic potential across numerous clinical disciplines. Its efficacy relies on concentrated platelets and plasma components that release growth factors, cytokines, and extracellular vesicles to orchestrate tissue repair, immunomodulation, and angiogenesis. Recent findings have uncovered novel mechanisms, such as mitochondrial transfer from platelets to target cells and the delivery of bioactive microRNAs that regulate inflammation and metabolic reprogramming. However, despite its potential, PRP therapy is often limited by inconsistent results. In this review, we examine how patient-specific factors-including age, comorbidities, and lifestyle-and technical variables in preparation and storage, influence the biological quality of the final product. Therefore, standardizing protocols and accounting for individual biological variability are essential for achieving reproducible outcomes. In conclusion, PRP is a complex therapeutic agent whose success depends on both intrinsic bioactive content and extrinsic processing factors. Integrating these molecular insights with personalized patient assessment is crucial to optimizing PRP treatment procedures. Future research should focus on refining standardization to fully establish PRP as a precision medicine tool in regenerative therapy.

Indexed as

Platelet-Rich PlasmaPrecision MedicineRegenerative MedicineAnimalsHumansIntercellular Signaling Peptides and ProteinsIntercellular Signaling Peptides and Proteinsaginganticoagulantblood cellscentrifugationcytokinesdietgrowth factorslaboratory medicinepre-analytical phase

Identifiers

PMID41596701
PMCPMC12842059

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.